GeneCentrix

Need to get back to work, but can't stop "testing" our latest version of HistoReceptomics 😂. It has improved features, interface and speed and makes and a whole lot easier. Register for your free trial here: https://historeceptomics.com

GeneCentrix recognizes the holiday , commemorating the official end of slavery in the United States, and will be closed for company business tomorrow. We encourage our brother and sister companies in the and fields to recognize this holiday in any way they can and give their employees the opportunity to reflect on our collective struggle towards a better, more just society. We stand with all those who have been suffering injustice and with all people everywhere who are fighting for human rights and for the health and well-being of all world citizens.

Join us tomorrow! Research Director, Dr. Jennifer Fuller, will discuss how our platform, , uses an elegant metric to rate chemical libraries by their suitability for phenotypic screens.

Explore the current state of computational methods used in phenotypic screening and novel in silico approaches, with discussions on deep learning, AI, functional genomics, chemical screening, systems biology, target deconvolution, biomarkers, and toxicity. Join us tomorrow: https://bit.nyas.org/2STTGN9

Happy 20th to us! The 20th issue of our newsletter and blog, Attrition Zero (subscribe) is out. It’s on (duh): , , screens. Plus a cool we're sponsoring that you should really attend (more later). Happy reading: https://mailchi.mp/9d641a0e5f53/gc-covid-1371656

COVID-19 Special Issue 2: Mutation and the (more) sick factor, phenotypic screen stars (plus a meeting!), & vaccines: fast & spurious? COVID-19 continues to mature and consolidate into something which we can wrap our heads around better. One of the recent kerfuffles has been about the significance of a particular point mutation in the virus.  Is it a more contagious or dangerous form?

Eureka! Our updated HistoReceptomics platform for , with even greater capability (tissue search) and looks (ahem) is almost ready to launch! Here's a sneak peak, available next week. Sign up ahead of time for a free trial: https://www.genecentrix.com/free-trial

Time sure is funny under , but somehow the BIG DAY (or rather two days, June 4-5) that we have been planning and preparing for here at are almost here. Why are we excited? A little thing called . You see, our platform just happens to be perfectly suited to enhancing the efficiency of phenotypic screens by integrating and target expression into compound evaluation. So, we developed a simple (but we think very cool) metric to score chemical libraries according to their suitability for phenotypic screens. And now we will be presenting the work at a big ol' virtual put on by The New York Academy of Sciences: "Phenotypic Drug Discover: Leveraging Tools." So join us and folks from Pfizer, Princeton University, Massachusetts Institute of Technology (MIT), Columbia University in the City of New York, GlaxoSmithKline, Recursion Pharmaceuticals, MD Anderson Cancer Center and many others. It'll be a deep dive into , , functional , systems biology, chemical screening, target deconvolution, biomarkers, target deconvolution, toxicity and more! It's not too late to register now: https://bit.ly/2X7ZVza. Be there (virtually) and enter the future of with us!

Phenotypic Drug Discovery: Leveraging Computational Tools | The New York Academy of Sciences Explore the current state of computational methods used in phenotypic screening and novel in silico approaches, and include discussions of deep learning, AI, functional genomics, chemical screening, systems biology, target deconvolution, biomarkers, and toxicity

Join Olga Troyanskaya, other folks, from (Pfizer) to Academe (Columbia University in the City of New York)–and us!––for this rad exploration of cutting edge Screening, sponsored by the New York Academy of Sciences, N.Y.A.S. If you're into , or (think ), you won't want to miss this state-of-the-science discussion June 4-5. Register here today: https://bit.nyas.org/2STTGN9

Olga Troyanskaya, whose research centers around and functional genomics, will give a keynote talk at our “Phenotypic Drug Discovery” two-day virtual conference. Learn more and register here: https://bit.nyas.org/2STTGN9

Advances in have led to a veritable deluge of , ironically SLOWING DOWN the process (oops). But a June at The New York Academy of Sciences will feature and solutions to the too-much-of-a-good-thing problem, including our very own , a powerful reducer and target enabler. Join us, Olga Troyanasaka of Princeton University and the Simons Foundation, Mike White, Ph.D. from Pfizer, and many more cool peeps–and don't miss our talk on Thursday, June 4 : "Historeceptomics Impoves the Yield of Phenotypic Screens." https://buff.ly/3caK0VG

Phenotypic Drug Discovery: Leveraging Computational Tools | The New York Academy of Sciences Explore the current state of computational methods used in phenotypic screening and novel in silico approaches, and include discussions of deep learning, AI, functional genomics, chemical screening, systems biology, target deconvolution, biomarkers, and toxicity

Join Us! We'll be (Virtually) Puttin' on the Ritz for Newark Venture Partners and Windham Venture Partners at the NYU Leslie eLab and NYU Entrepreneur VC Pitch Fest tomorrow at 5pm. Grab your e-tix here: https://bit.ly/2UU1YG3

VC Pitchfest (Healthcare & Life Science) - April 9th Virtual VC Pitchfest (Healthcare) on Thursday, April 9th (5 - 7 pm) Hear Pitches from: Portable Diagnostic Systems: A veteran-owned startup developingnext-generation sobriety detection technology for law enforcement and workforce. GeneCentrix: The startup provides software & data science solutions f...

Find yourself with a little , plus an interest in , , or just a thing for way cool ? You've come to the right . Catch up on everything , and dreaded drug failures (and how to avoid them) with our and : https://lnkd.in/dg-ieYZ. And don't forget to sign up here to get it every month: https://bit.ly/39Uftd5 . . .Happy reading!

We help companies with drug , so check out our latest newsletter with expert thoughts on the potential of & older drugs by Fujifilm USA and Gilead Sciences in the fight against . https://bit.ly/2V0IGxu

COVID-19 Special Issue: On cautions, cross-reactions & cures “It’s almost like the fog of war. After the war is over, you then look back and say, ‘Wow, this plan, as great as it was, didn’t quite work once they started that throwing hand grenades at us.'" 

Hydroxychloroquine combined with Azithromycin is getting attention as a possible COVID-19 treatment before a vaccine is found. Using our knowledge of tissue specificity in drug development, we break down the hidden reasons these drugs might be effective. https://bit.ly/2R9bqTE

Surface charm A small pilot study from France showed that all 6 COVID-19 patients given a hydroxychloroquine/azithromycin combination recovered quickly from the disease, des

Read our new post on the science behind why the treatment potential of by Fujifilm USA and by Gilead Sciences might be very good . . . https://bit.ly/2UYFv9k

Nucleic freeze While the protease inhibitor similarity flopped for COVID-19, that doesn’t mean that the line of reasoning of drugs cro

GeneCentrix updated their business hours.

GeneCentrix updated their phone number.

GeneCentrix updated their website address.

It's now easier to contact GeneCentrix.